Guanfacine treatment of cognitive impairment in schizophrenia

Joseph I. Friedman; David N. Adler; Humberto D. Temporini; Eileen Kemether; Philip D. Harvey; Leonard White; Michael Parrella; Kenneth L. Davis

doi:10.1016/S0893-133X(01)00249-4

Guanfacine treatment of cognitive impairment in schizophrenia

Joseph I. Friedman, David N. Adler, Humberto D. Temporini, Eileen Kemether, Philip D. Harvey, Leonard White, Michael Parrella, Kenneth L. Davis

Research output: Contribution to journal › Article › peer-review

107 Scopus citations

Abstract

Norepinephrine plays a significant role in the working memory functions of the prefrontal cortex by its actions at alpha-2a noradrenergic receptors. Guanfacine has demonstrated efficacy in reversing working memory deficits in non-human primate. In the present study the effect of guanfacine adjunctive treatment to neuroleptics on the cognitive performance of schizophrenic patients was investigated in a four week, placebo-controlled, double-blind, parallel design trial. The primary analyses revealed no significant differences between guanfacine and placebo treatment; however, exploratory non-parametric statistics revealed some significant and some trend differences between guanfacine and placebo on spatial working memory test performance and CPT reaction time in those subjects treated with atypical neuroleptics.

Original language	English (US)
Pages (from-to)	402-409
Number of pages	8
Journal	Neuropsychopharmacology
Volume	25
Issue number	3
DOIs	https://doi.org/10.1016/S0893-133X(01)00249-4
State	Published - 2001
Externally published	Yes

Keywords

Clinical Trial
Cognitive
Guanfacine
Norepinephrine
Schizophrenia

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/S0893-133X(01)00249-4

Cite this

@article{92d9022535334a739b411448fb06a76a,

title = "Guanfacine treatment of cognitive impairment in schizophrenia",

abstract = "Norepinephrine plays a significant role in the working memory functions of the prefrontal cortex by its actions at alpha-2a noradrenergic receptors. Guanfacine has demonstrated efficacy in reversing working memory deficits in non-human primate. In the present study the effect of guanfacine adjunctive treatment to neuroleptics on the cognitive performance of schizophrenic patients was investigated in a four week, placebo-controlled, double-blind, parallel design trial. The primary analyses revealed no significant differences between guanfacine and placebo treatment; however, exploratory non-parametric statistics revealed some significant and some trend differences between guanfacine and placebo on spatial working memory test performance and CPT reaction time in those subjects treated with atypical neuroleptics.",

keywords = "Clinical Trial, Cognitive, Guanfacine, Norepinephrine, Schizophrenia",

author = "Friedman, {Joseph I.} and Adler, {David N.} and Temporini, {Humberto D.} and Eileen Kemether and Harvey, {Philip D.} and Leonard White and Michael Parrella and Davis, {Kenneth L.}",

year = "2001",

doi = "10.1016/S0893-133X(01)00249-4",

language = "English (US)",

volume = "25",

pages = "402--409",

journal = "Neuropsychopharmacology",

issn = "0893-133X",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Guanfacine treatment of cognitive impairment in schizophrenia

AU - Friedman, Joseph I.

AU - Adler, David N.

AU - Temporini, Humberto D.

AU - Kemether, Eileen

AU - Harvey, Philip D.

AU - White, Leonard

AU - Parrella, Michael

AU - Davis, Kenneth L.

PY - 2001

Y1 - 2001

N2 - Norepinephrine plays a significant role in the working memory functions of the prefrontal cortex by its actions at alpha-2a noradrenergic receptors. Guanfacine has demonstrated efficacy in reversing working memory deficits in non-human primate. In the present study the effect of guanfacine adjunctive treatment to neuroleptics on the cognitive performance of schizophrenic patients was investigated in a four week, placebo-controlled, double-blind, parallel design trial. The primary analyses revealed no significant differences between guanfacine and placebo treatment; however, exploratory non-parametric statistics revealed some significant and some trend differences between guanfacine and placebo on spatial working memory test performance and CPT reaction time in those subjects treated with atypical neuroleptics.

AB - Norepinephrine plays a significant role in the working memory functions of the prefrontal cortex by its actions at alpha-2a noradrenergic receptors. Guanfacine has demonstrated efficacy in reversing working memory deficits in non-human primate. In the present study the effect of guanfacine adjunctive treatment to neuroleptics on the cognitive performance of schizophrenic patients was investigated in a four week, placebo-controlled, double-blind, parallel design trial. The primary analyses revealed no significant differences between guanfacine and placebo treatment; however, exploratory non-parametric statistics revealed some significant and some trend differences between guanfacine and placebo on spatial working memory test performance and CPT reaction time in those subjects treated with atypical neuroleptics.

KW - Clinical Trial

KW - Cognitive

KW - Guanfacine

KW - Norepinephrine

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0034887916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034887916&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(01)00249-4

DO - 10.1016/S0893-133X(01)00249-4

M3 - Article

C2 - 11522468

AN - SCOPUS:0034887916

VL - 25

SP - 402

EP - 409

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 3

ER -

Guanfacine treatment of cognitive impairment in schizophrenia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this